Mereo BioPharma is no longer the setrusumab launch story the market priced through late last year. A late-December readout from the Orbit and Cosmic studies missed the primary fracture-rate endpoints that were supposed to open a first approval in osteogenesis imperfecta. Bone mineral density still improved with high statistical significance, and pediatric patient-reported outcomes moved in a favorable direction, but the fracture miss collapsed the near-term commercial narrative. The equity now prices residual optionality on two partnered programs rather than a first European launch.
The August reset is the Sentynl Therapeutics option on alvelestat, an oral neutrophil-elastase inhibitor for alpha-1 antitrypsin deficiency lung disease. Sentynl is a Zydus Lifesciences subsidiary that already sells a small slate of approved rare-disease products. Exercise would deliver $40 million in upfront and research payments plus funding for a late-stage trial that Mereo would still lead. Cash at mid-year sat near $30 million. Management now guides that balance into late 2027 even before any option payment, because manufacturing and European pre-commercial spend on setrusumab has been cut.
The strongest counterargument is that the Sentynl contract is still only an option, setrusumab still lacks a defined regulatory path, and Nasdaq has already issued a second bid-price notice with a mid-February 2027 deadline. The ADS last changed hands near thirty cents against a one-dollar listing floor. Whether Sentynl exercises, and whether the Food and Drug Administration allows an alternative fracture analysis for pediatric patients, decides if this is a funded pipeline stub or a listing-risk cash remainder.